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A commentary on
Development, implementation, and com-
pliance of treatment pathways in radiation 
medicine
by Potters L, Raince J, Chou H, Kapur A, 
Bulanowski D, Stanzione R, et al. Front. 
Oncol. (2013). doi:10.3389/fonc.2013.00105
We read the article by Dr. Louis Potters et al. 
with great interest and we laud their team’s 
effort to standardize care around evidenced-
based clinical pathways. In addition to 
improving safety and bending the cost curve, 
standardizing clinical practice around expert 
clinical pathways has several additional ben-
efits which we would like to highlight.
First, there is a growing body of literature 
from clinical trial cooperative groups that 
suggest adherence to protocol is associated 
with improved outcomes. Indeed, in some 
cases, the benefits of protocol adherence may 
even be larger than the advanced technologies 
or novel drug being evaluated. For example, 
Abrams et al. (1) conducted a planned sec-
ondary analysis of RTOG 9704 trial, a phase 
III adjuvant chemo-radiation protocol for 
pancreatic adenocarcinoma in order to deter-
mine whether protocol compliance status 
was associated with survival. Patients with 
major protocol deviations had significantly 
lower survival even after controlling for other 
known confounders and study arm. Similarly, 
in a recent meta-analysis, radiation protocol 
deviations were associated with increased risk 
of treatment failure and mortality (2).
Second, adherence to standardized clini-
cal pathways may also decrease the overall 
variability of clinical outcomes allowing 
research groups and clinical practices to 
more easily identify new treatments that 
actually improve care. For instance, consider 
TROG 02.02 a phase III trial of head and 
neck cancer chemo-radiation with or with-
out tirapazamine, a hypoxic cell cytotoxin 
(3). Overall, the study found no evidence 
of improvement in local-regional control 
in patients who received tirapazamine. 
However, secondary analyses suggested a 
small benefit to the experimental drug, but 
only in the subset of patients who received 
radiation therapy of an acceptable standard.
Third, clinical pathways would also 
promote standardization of the terminol-
ogy used to describe treatments within 
EMRs, greatly increasing the value of 
EMR-based registries. There are sev-
eral important nationally representative 
EMR-based registry efforts under way 
including the Oncology Data Alliance, the 
National Radiation Oncology Registry, and 
CancerLinQ. These efforts will be limited by 
the fact that the same treatment technique 
can be described in many different ways 
within EMRs (e.g., “VMAT” vs. “Rotational 
Arc”). A clinical pathways program would 
reduce the number of ways the same treat-
ments are described within and across can-
cer programs.
As Potters et al. mention in their discus-
sion, manufacturing and other industries 
have long ago embraced standardization. 
Since the late 1980s, medical device manu-
facturers have been required to comply 
with standards from the International 
Organization of Standardization (ISO) 
resulting in not only more consistent 
and predictable product quality, but also 
clear improvements in product safety and 
 efficacy. Clinical pathways programs could 
bring the same benefits to cancer clinics and 
their patients. We encourage program lead-
ers to make note of the article by Potters 
et al. and EMR vendors to develop func-
tionality to support such efforts.
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